Loading organizations...
§ Private Profile · San Carlos, CA, USA
Medical technology company developing and commercializing pulsed electric field (PEF) therapies for oncology and chronic lung disease.
Redwood City, California-based Galvanize Therapeutics is a medical technology company that develops and commercializes pulsed electric field therapies for oncology and chronic lung disease. The organization focuses on non-thermal energy devices, providing the Aliya platform for solid tumors and the RheOx system for chronic bronchitis symptoms. These medical devices are currently utilized by physicians across approximately 70 hospitals in the United States, having treated around 3,000 patients. Galvanize Therapeutics has secured significant venture capital to scale its operations, including a $100 million Series C round in September 2025 and a prior $100 million Series B. This financial backing was drawn from a syndicate of prominent investors such as Sofinnova Partners, Fidelity, Intuitive Surgical, and Apple Tree Partners. The enterprise was established in 2022 through the merger of existing portfolio companies by founder Jonathan Waldstreicher.
Galvanize Therapeutics has raised $200.0M across 2 funding rounds.
Galvanize Therapeutics has raised $200.0M in total across 2 funding rounds.
Galvanize Therapeutics has raised $200.0M across 2 funding rounds. Most recently, it raised $100.0M Series C in September 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2025 | $100M Series C | Soffinova Partners | Jonathan Waldstreicher, Seth L. Harrison, ATP (apple Tree Partners), Norwest Venture Partners, Ally Bridge Group, Apple Tree Partners, Elevage Medical Technologies, Fidelity Management & Research Company, David Lewis, Intuitive Ventures, Janus Henderson Investors, Longaeva, Zack Scott, Perceptive Xontogeny Venture Fund, T. Rowe Price Associates | Announced |
| Sep 1, 2022 | $100M Series B | Fidelity Management & Research Company | Jonathan Waldstreicher, Seth L. Harrison, ATP (apple Tree Partners), Norwest Venture Partners, Soffinova Partners, Apple Tree Partners, Gilmartin Capital, Intuitive Ventures | Announced |
Galvanize Therapeutics is a commercial-stage biomedical company developing pulsed electric field (PEF) technologies to treat diseases like solid tumors and chronic bronchitis by targeting pathologic cells non-thermally.[1][2][3] Its key products include the Aliya® PEF platform for oncology, aimed at ablating solid tumors and potentially stimulating immune responses, and RheOx® therapy for chronic bronchitis symptoms, addressing underserved patients beyond pharmaceutical options.[1][3][4] The company serves physicians, healthcare systems, and patients with these innovations, solving problems of limited efficacy in current treatments for metastatic cancers and debilitating lung conditions; it demonstrates strong growth momentum through a $100 million oversubscribed Series C in September 2025, FDA approvals for commercialization in the US, ongoing clinical trials, and board expansions.[1][3]
Galvanize Therapeutics emerged in late 2022 from a three-way merger of Apple Tree Partners (ATP) portfolio companies, each developing pulsed field ablation technologies for solid tumors, chronic bronchitis, and arrhythmias.[1][2] Incubated by ATP, a venture firm focused on biotech innovations, the company was formed in Redwood City, California, to consolidate and accelerate PEF platforms like Aliya and RheOx.[1][2][3] Early traction included first-in-human studies for RheOx showing safety and efficacy in chronic bronchitis, histopathologic validations, and pivotal clinical data presented in abstracts, setting the stage for US commercialization.[1][4]
Galvanize rides the wave of electroporation and PEF therapies in medtech, converging engineering, biology, and precision healthcare to challenge pharma-dominated treatments for oncology and chronic lung diseases.[2][3] Timing aligns with surging demand for non-invasive, immune-modulating alternatives amid rising cancer/metastatic cases and COPD burdens, bolstered by FDA nods and post-2025 funding for US expansion.[1][3] Market forces like underserved millions in solid tumors/chronic bronchitis favor its platform, influencing the ecosystem by pioneering PEF commercialization, fostering physician partnerships, and enabling data synergies with drugs.[2][3][4]
Galvanize is poised to scale US commercialization of Aliya and RheOx post-Series C, with funds fueling clinical expansion, platform innovation, and global ambitions beyond current US focus.[3] Trends like AI-driven trial design, immune-oncology synergies, and non-pharma chronic disease interventions will propel it, potentially evolving from PEF pioneer to global leader reshaping ablation standards.[1][3] As a 2022 merger success, its trajectory ties back to ATP's vision: delivering biologic-shifting medtech for patients long overlooked by pills alone.[1][2]
Galvanize Therapeutics has raised $200.0M in total across 2 funding rounds.
Galvanize Therapeutics's investors include Soffinova Partners, Jonathan Waldstreicher, Seth L. Harrison, ATP (Apple Tree Partners), Norwest Venture Partners, Ally Bridge Group, Apple Tree Partners, Elevage Medical Technologies, Fidelity Management & Research Company, David Lewis, Intuitive Ventures, Janus Henderson Investors.